PHAT
Phathom Pharmaceuticals, Inc.
1W: -4.5%
1M: -9.8%
3M: -41.4%
YTD: -33.4%
1Y: +59.9%
3Y: +62.8%
5Y: -75.2%
$10.47
+0.41 (+4.08%)
After Hours: $10.78 (+0.31, +2.96%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$2.3M
Congress—
ETF Holdings—
Key Statistics
Market Cap$825.0M
52W Range2.21-18.31
Volume836,533
Avg Volume1,122,179
Beta0.56
Dividend—
Analyst Ratings
Company Info
CEOSteven L. Basta
Employees427
SectorHealthcare
IndustryBiotechnology
IPO Date2019-10-25
Websitephathompharma.com
100 Campus Drive
Florham Park, NJ 07932
US
Florham Park, NJ 07932
US
877 742 8466
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Latest News
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.25 Consensus PT from Brokerages
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Parikh Asit | G-Gift | 40,000 | — | 2026-03-10 |
| Parikh Asit | G-Gift | 40,000 | — | 2026-03-10 |
| Breedlove Robert Cha | A-Award | 13,000 | — | 2026-02-27 |
| Breedlove Robert Cha | A-Award | 2,790 | — | 2026-02-27 |
| Breedlove Robert Cha | F-InKind | 964 | $12.56 | 2026-02-27 |